Chiesi Group to Acquire KalVista Pharmaceuticals in $1.9 Billion All-Cash Deal

Key Facts

Italian pharmaceutical giant Chiesi Group has entered into a definitive agreement to acquire KalVista Pharmaceuticals (Nasdaq: KALV) in an all-cash transaction valued at approximately $1.9 billion. Following the announcement, KALV share prices climbed significantly as investors reacted positively to the acquisition terms. The deal has received unanimous approval from the boards of both companies and is expected to close in the third quarter of 2026, pending regulatory clearances. This strategic move marks a major expansion for Chiesi into the U.S. market and strengthens its portfolio of innovative treatments. The market's bullish response underscores a broader trend of consolidation within the global biotech sector. By integrating KalVista’s assets, Chiesi aims to solidify its international footprint and drive long-term growth.

Version History